Drug development - Lupus drug company asks FDA for second chance

被引：4
|
作者：
Couzin, J
机构：
来源：
SCIENCE | 2005年 / 307卷 / 5711期
关键词：
D O I：
10.1126/science.307.5711.835
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
The safety of LJP 394, produced by La Jolla Pharmaceutical Company, for the treatment of lupus is discussed. FDA approval, clinical trials, and adverse effects are also discussed.
引用
收藏
页码：835 / 835
页数：1
相关论文
共 50 条
  • [31] FDA's role in anesthetic drug development
    Landow, L
    Kahn, RC
    Wright, C
    ANESTHESIOLOGY, 1999, 90 (03) : 882 - 889
  • [32] FDA regulatory considerations for oncology drug development
    Moon, Hanlim
    Zang, Dae Young
    Ryu, Min-Hee
    Seo, Yeonsook
    Oh, Bitna
    Hwang, Sunjin
    Farrand, Lee
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (04):
  • [33] Flexibility in the FDA approach to orphan drug development
    Hunter, Nina L.
    Rao, Gayatri R.
    Sherman, Rachel E.
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (11) : 737 - 738
  • [34] Pediatric drug development in anesthesiology: an FDA perspective
    Schultheis, LW
    Mathis, LL
    Roca, RA
    Simone, AF
    Hertz, SH
    Rappaport, BA
    ANESTHESIA AND ANALGESIA, 2006, 103 (01): : 49 - 51
  • [35] FDA: Evidentiary Standards for Drug Development and Approval
    Katz R.
    NeuroRX, 2004, 1 (3): : 307 - 316
  • [36] New FDA recommendations to speed drug development
    Shalev M.
    Lab Animal, 2006, 35 (3) : 13 - 13
  • [37] FDA and Evidence-Based Drug Development
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (02) : 10N - 11N
  • [38] FDA ISSUES DRAFT CONCEPT PAPER ON DRUG COMPANY FUNDING OF CME
    SKOLNICK, AA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (21): : 2947 - 2948
  • [39] DRUG COMPANY SPONSORSHIP OF EDUCATION - THE RESPONSE TO THE FDA DRAFT CONCEPT PAPER
    LAZAR, EJ
    BANKS, D
    GRAHAM, C
    ADAMS, D
    RHEINSTEIN, PH
    GROSS, M
    WITT, AM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (01): : 53 - 54
  • [40] FDA Guidance on Drug Development for Early AD
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (04) : 14N - 14N
12345